Regeneron Pharmaceuticals, Inc. (REGN)

333.34
NASDAQ
Prev Close 333.34
Day Low/High 0.00 / 0.00
52 Wk Low/High 281.89 / 442.00
Exchange NASDAQ
Shares Outstanding 109.28B
Market Cap 36.43B
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

2 Well-Known Stocks to Consider Shorting Thanksgiving Week

2 Well-Known Stocks to Consider Shorting Thanksgiving Week

These 'Bearish Bets' are showing both technical and quantitative deterioration.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Regeneron Soars After My 'Go Long' Recommendation: What Now?

Regeneron Soars After My 'Go Long' Recommendation: What Now?

An updated strategy for the high-flying REGN.

Regeneron Is Leading the Way for Biotech

Regeneron Is Leading the Way for Biotech

Recent action tells us REGN's momentum is super strong.

Jim Cramer: Move Over FANG, Long Live INJFANG

Jim Cramer: Move Over FANG, Long Live INJFANG

The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.

Aggressive Traders Must Go Long Regeneron Pharmaceuticals

Aggressive Traders Must Go Long Regeneron Pharmaceuticals

We have more evidence to support the bull case.

Regeneron Downtrend Ending But No Rush to Buy

Regeneron Downtrend Ending But No Rush to Buy

Stock still needs a period of base building to support advance.

Regeneron Downgraded at Raymond James

12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction

12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction

Thanks to the stock market correction many world-class stocks are back down to attractive levels.

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet

Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet

Traders and investors should stand aside until the situation with this biotech name offers a better entry point.

Investors Shun Biotech Stocks

Investors Shun Biotech Stocks

The speed at which investors have bailed on this sector is alarming.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Regeneron Cut to Underweight at Barclays

Stalking Regeneron for Key Low and Reversal

Stalking Regeneron for Key Low and Reversal

Many swings on a particular chart tend to be similar to others.

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Shares have regained their 50-day moving average and look likely to push higher.

Regeneron Cut to Underperform at Baird

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Cramer: This Is No Country for Old Value

Cramer: This Is No Country for Old Value

Down-and-out stocks have become toxic.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.